GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiasma Inc (NAS:CHMA) » Definitions » Financial Strength

Chiasma (Chiasma) Financial Strength : 0 (As of Mar. 2021)


View and export this data going back to 2015. Start your Free Trial

What is Chiasma Financial Strength?

Chiasma has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Chiasma did not have earnings to cover the interest expense. Chiasma's debt to revenue ratio for the quarter that ended in Mar. 2021 was 0.00. As of today, Chiasma's Altman Z-Score is -2.41.


Competitive Comparison of Chiasma's Financial Strength

For the Biotechnology subindustry, Chiasma's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chiasma's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiasma's Financial Strength distribution charts can be found below:

* The bar in red indicates where Chiasma's Financial Strength falls into.



Chiasma Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Chiasma's Interest Expense for the months ended in Mar. 2021 was $-12.46 Mil. Its Operating Income for the months ended in Mar. 2021 was $-18.04 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2021 was $0.00 Mil.

Chiasma's Interest Coverage for the quarter that ended in Mar. 2021 is

Chiasma did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Chiasma's Debt to Revenue Ratio for the quarter that ended in Mar. 2021 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2021 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 7.696
=0.00

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Chiasma has a Z-score of -2.41, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -2.41 is in distress zone. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chiasma  (NAS:CHMA) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Chiasma has the Financial Strength Rank of 0.


Chiasma Financial Strength Related Terms

Thank you for viewing the detailed overview of Chiasma's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Chiasma (Chiasma) Business Description

Traded in Other Exchanges
N/A
Address
140 Kendrick Street, Building C East, Needham, MA, USA, 02494
Chiasma Inc is a commercial-stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for rare and serious chronic disease. The US Food and Drug Administration, or the FDA, approved MYCAPSSA for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog, or SSA, approved by the FDA and the first product approved by the FDA utilizing TPE technology. The company is focused on the commercialization of MYCAPSSA for the treatment of patients with acromegaly in the United States and developing and seeking regulatory approval of MYCAPSSA in the European Union.
Executives
Roni Mamluk director CHIASMA, INC., 60WELLS AVENUE, NEWTON MA 02459
David M Stack director THE MEDICINES CO, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Raj Kannan director, officer: Chief Executive Officer C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
John F Thero director C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921
Bard Geesaman director C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142
Todd Foley director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
John A Scarlett director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Scott Minick director C/O BIND THERAPEUTICS, INC. 325 VASSAR ST CAMBRIDGE MA 02139
Anand Varadan officer: EVP, Chief Commerical Officer C/O CHIASMA, INC., 60 WELLS AVENUE, NEWTON MA 02459
Lee Giguere officer: General Counsel C/O CHIASMA, INC. 460 TOTTEN POND ROAD, SUITE 530 WALTHAM MA 02451
William Ludlam officer: See Remarks C/O CHIASMA, INC. 460 TOTTEN POND ROAD, SUITE 530 WALTHAM MA 02451
Drew Enamait officer: VP, Fin & Admin, PAO C/O CHIASMA, INC. 275 WYMAN STREET, SUITE 250 WALTHAM MA 02451
Mark J. Fitzpatrick officer: President 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
James R Tobin director C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ansbert Gadicke director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116